Details of Disease

General Information of Disease (ID: DIS8BMO7)

• Disease Name: Growth hormone deficiency
• Disease Class: 5A60-5A61: Pituitary gland disorder
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS8BMO7: Growth hormone deficiency
• ICD Code:
  ICD-11: ICD-11: 5A61.3
  Expand ICD-11: '5A61.3
  Expand ICD-9: 253.0,253.3
• Disease Identifiers:
  MedGen ID: 82880
  SNOMED CT ID: 397827003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Arginine	DMRE4FC	Approved	Small molecular drug	[1]
GHRP-2	DMKGH0R	Approved	Small molecular drug	[1]
Lonapegsomatropin	DMPR8E9	Approved	NA	[2]
Macimorelin	DMQYJIR	Approved	Small molecular drug	[3]
Somapacitan	DM7CNBW	Approved	Peptide	[4]
Somatotropin rdna	DMB3DEG	Approved	NA	[1]
Somatrogon	DMSUSTL	Approved	Peptide	[5]
Somatropin biosimilar	DM8UHG7	Approved	NA	[6]
Somatropin recombinant	DMF3GM2	Approved	NA	[7]

This Disease is Treated as An Indication in 12 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
HGH-CTP	DMXAZ47	Phase 3	NA	[8]
Somavaratan	DMEWHNB	Phase 3	NA	[3]
TV-1106	DMMUB2W	Phase 3	NA	[3]
VRS-317	DMWMT5N	Phase 3	NA	[9]
Ibutamoren mesylate	DMN2CM0	Phase 2	Small molecule	[10]
Long-acting hGH conjugate	DM9CG2H	Phase 2	NA	[11]
NN-8630	DM4O123	Phase 2	NA	[12]
PH-794428	DM71HVW	Phase 2	NA	[13]
SKF-110679	DMNRHMX	Phase 2	Small molecular drug	[14]
Somatropin intranasal rhGH	DMK3RL8	Phase 2	NA	[15]
Tabimorelin	DMNL9HO	Phase 2	Small molecular drug	[16]
YPEG-Somatropin	DMCM0K6	Phase 1	NA	[17]

This Disease is Treated as An Indication in 4 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Examorelin	DMGJMQH	Discontinued in Phase 2	Small molecular drug	[18]
L-692429	DMLHE5A	Discontinued in Phase 1	Small molecular drug	[19]
LY-444711	DMNPJL3	Discontinued in Phase 1	NA	[20]
NNC-26-0762	DMLTYFI	Terminated	NA	[21]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Growth hormone	DMM5YJL	Investigative	NA	[22]
Growth hormone releasing factor peptides	DM5III8	Investigative	NA	[22]
P-1118	DMFU5V3	Investigative	NA	[22]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761184
• [6] Current Status of Biosimilar Growth Hormone. Int J Pediatr Endocrinol. 2009; 2009: 370329.
• [7] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [8] ClinicalTrials.gov (NCT01909479) A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT02339090) Comparison of Long-acting Growth Hormone VRS-317 to Daily Growth Hormone in Pediatric GHD Patients. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT05364684) The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study. U.S.National Institutes of Health.
• [11] ClinicalTrials.gov (NCT01822340) Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT00715689) Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT00308464) A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency. U.S. National Institutes of Health.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093).
• [15] ClinicalTrials.gov (NCT00837863) Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency. U.S. National Institutes of Health.
• [16] Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
• [17] ClinicalTrials.gov (NCT01339182) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers. U.S. National Institutes of Health.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1100).
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5868).
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012573)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010046)
• [22] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.